These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 26523202)

  • 1. Epigenetic mechanisms in non-alcoholic fatty liver disease: An emerging field.
    Gallego-Durán R; Romero-Gómez M
    World J Hepatol; 2015 Oct; 7(24):2497-502. PubMed ID: 26523202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetics in non-alcoholic fatty liver disease.
    Lee J; Kim Y; Friso S; Choi SW
    Mol Aspects Med; 2017 Apr; 54():78-88. PubMed ID: 27889327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic mechanisms underlying the link between non-alcoholic fatty liver diseases and nutrition.
    Lee JH; Friso S; Choi SW
    Nutrients; 2014 Aug; 6(8):3303-25. PubMed ID: 25195642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and diagnosis of NAFLD/NASH.
    Hashimoto E; Taniai M; Tokushige K
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():64-70. PubMed ID: 24251707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A crosstalk between epigenetic modulations and non-alcoholic fatty liver disease progression.
    Ramezani M; Zobeiry M; Abdolahi S; Hatami B; Zali MR; Baghaei K
    Pathol Res Pract; 2023 Nov; 251():154809. PubMed ID: 37797383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic and epigenetic disease modifiers: non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD).
    Choudhary NS; Duseja A
    Transl Gastroenterol Hepatol; 2021; 6():2. PubMed ID: 33409397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PNPLA3 genotype increases susceptibility of nonalcoholic steatohepatitis among obese patients with nonalcoholic fatty liver disease.
    Tai CM; Huang CK; Tu HP; Hwang JC; Chang CY; Yu ML
    Surg Obes Relat Dis; 2015; 11(4):888-94. PubMed ID: 25240529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
    Clemente MG; Mandato C; Poeta M; Vajro P
    World J Gastroenterol; 2016 Sep; 22(36):8078-93. PubMed ID: 27688650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysregulated Epigenetic Modifications in the Pathogenesis of NAFLD-HCC.
    Zhao F
    Adv Exp Med Biol; 2018; 1061():79-93. PubMed ID: 29956208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetics: An emerging field in the pathogenesis of nonalcoholic fatty liver disease.
    Ashraf NU; Altaf M
    Mutat Res Rev Mutat Res; 2018; 778():1-12. PubMed ID: 30454678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetics in NAFLD/NASH: Targets and therapy.
    Sodum N; Kumar G; Bojja SL; Kumar N; Rao CM
    Pharmacol Res; 2021 May; 167():105484. PubMed ID: 33771699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Non-alcoholic fatty liver disease--new view].
    Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P
    Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetics and epigenetics of NAFLD and NASH: Clinical impact.
    Eslam M; Valenti L; Romeo S
    J Hepatol; 2018 Feb; 68(2):268-279. PubMed ID: 29122391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.
    Vernon G; Baranova A; Younossi ZM
    Aliment Pharmacol Ther; 2011 Aug; 34(3):274-85. PubMed ID: 21623852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential epigenetic mechanism in non-alcoholic Fatty liver disease.
    Sun C; Fan JG; Qiao L
    Int J Mol Sci; 2015 Mar; 16(3):5161-79. PubMed ID: 25751727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
    Estes C; Anstee QM; Arias-Loste MT; Bantel H; Bellentani S; Caballeria J; Colombo M; Craxi A; Crespo J; Day CP; Eguchi Y; Geier A; Kondili LA; Kroy DC; Lazarus JV; Loomba R; Manns MP; Marchesini G; Nakajima A; Negro F; Petta S; Ratziu V; Romero-Gomez M; Sanyal A; Schattenberg JM; Tacke F; Tanaka J; Trautwein C; Wei L; Zeuzem S; Razavi H
    J Hepatol; 2018 Oct; 69(4):896-904. PubMed ID: 29886156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single non-invasive model to diagnose non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Otgonsuren M; Estep MJ; Hossain N; Younossi E; Frost S; Henry L; Hunt S; Fang Y; Goodman Z; Younossi ZM
    J Gastroenterol Hepatol; 2014 Dec; 29(12):2006-13. PubMed ID: 25039333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The diagnosis and treatment of non-alcoholic fatty liver disease.
    Altinbas A; Sowa JP; Hasenberg T; Canbay A
    Minerva Gastroenterol Dietol; 2015 Sep; 61(3):159-69. PubMed ID: 26080905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease.
    Panera N; Gnani D; Crudele A; Ceccarelli S; Nobili V; Alisi A
    World J Gastroenterol; 2014 Nov; 20(41):15079-86. PubMed ID: 25386056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.